Search results for "Neoplastic"

showing 10 items of 2901 documents

Low Cross-Reactivity Between Cisplatin and Other Platinum Salts.

2019

Background Hypersensitivity reactions to platinum salts (PS) (cisplatin [CI], carboplatin [CA], and oxaliplatin [OX]) can be severe and their incidence is increasing due to their widespread use in cancer treatment. Objective To determine the rate of cross-reactivity between PS and whether CI can be administered without prior allergy testing in patients with a history of CA or OX hypersensitivity. Methods From September 2002 to April 2016, patients with suspected immediate PS hypersensitivity were tested and cross-reactivity between the 3 PS was evaluated. We then studied patients who were given CI without desensitization after immediate hypersensitivity to other PS. Results A total of 155 p…

AdultMalemedicine.medical_specialtyAllergymedicine.medical_treatment[SDV]Life Sciences [q-bio]Antineoplastic AgentsPlatinum CompoundsCross ReactionsGastroenterologyCarboplatinDrug Hypersensitivity03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineNeoplasmsImmunology and AllergyMedicineHumans030212 general & internal medicineDesensitization (medicine)AgedSkin TestsCisplatinAged 80 and overChemotherapybusiness.industryMiddle Agedmedicine.diseaseConfidence intervalCarboplatin3. Good healthOxaliplatinOxaliplatin030228 respiratory systemchemistryFemaleSaltsbusinessAnaphylaxismedicine.drugThe journal of allergy and clinical immunology. In practice
researchProduct

Total body irradiation and cyclophosphamide is a conditioning regimen for unrelated bone marrow transplantation in a patient with chronic myelogenous…

1998

Five years after the diagnosis of Ph chromosome-positive chronic myeloid leukemia (CML) a 31-year-old patient developed malignant nephrosclerosis with renal failure. He then underwent an allogeneic unrelated BMT in first chronic phase CML. The preparative regimen consisted of fractionated total body irradiation (TBI) and cyclophosphamide (CY). We studied the pharmacokinetics of cyclophosphamide on hemodialysis and compared clinical parameters including time to engraftment and toxicity with parameters of a patient with normal renal function who also received an unrelated marrow as treatment for CML in first chronic phase. Our results suggest that TBI/CY is a suitable conditioning regimen for…

AdultMalemedicine.medical_specialtyAllogeneic transplantationTransplantation ConditioningCyclophosphamidemedicine.medical_treatmentGastroenterologyRenal Dialysishemic and lymphatic diseasesInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansTransplantation HomologousAntineoplastic Agents AlkylatingCyclophosphamidePreparative RegimenBone Marrow TransplantationTransplantationChemotherapyNephrosclerosisbusiness.industryHematologyTotal body irradiationmedicine.diseaseSurgeryCase-Control StudiesKidney Failure ChronicHemodialysisbusinessWhole-Body Irradiationmedicine.drugKidney diseaseChronic myelogenous leukemiaBone marrow transplantation
researchProduct

Chemotherapy-induced mobilization of karyotypically normal PBSC for autografting in CML

1998

High-dose chemotherapy with autologous transplantation of in vivo purged PBSC is a new and interesting therapeutic option for CML patients not eligible for allogeneic transplantation. We investigated the feasibility and toxicity of this approach in 57 patients with Ph-positive CML. For mobilization of Ph-negative PBSC, patients were treated either with '5 + 2/7 + 3'- type chemotherapy or with 'mini-ICE/ICE' chemotherapy followed by administration of G-CSF. Fourteen patients were in early chronic phase, 30 patients in late chronic phase and 13 patients in accelerated phase (AP) or blast crisis (BC). Cytogenetic responses in the PBSC harvests were dependent on both disease stage and type of c…

AdultMalemedicine.medical_specialtyAllogeneic transplantationmedicine.medical_treatmentPilot ProjectsLeukemia Myelogenous Chronic BCR-ABL PositiveAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAutologous transplantationProspective StudiesEtoposideTransplantationMyelosuppressive ChemotherapyChemotherapybusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle AgedHematopoietic Stem Cell MobilizationGranulocyte colony-stimulating factorSurgeryTransplantationKaryotypingCytarabineFemalebusinessmedicine.drugBone Marrow Transplantation
researchProduct

Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94.

2003

Aim  The standard treatment for patients with clinically resectable rectal cancer is surgery. Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+). In recent years, encouraging results of pre-operative radiotherapy have been reported. This prospective randomized phase-III-trial (CAO/ARO/AIO-94) compares the efficacy of neoadjuvant RCT to standard postoperative RCT. We report on the design of the study and first results with regard to toxicity of RCT and postoperative morbidity. Patients and methods  Patients with locally advanced operable rectal cancer (uT3/4 or uN+, Mason CS III/IV) were randomly assigned to pre or postoperative RCT: A total dose of 50.4…

AdultMalemedicine.medical_specialtyAntimetabolites AntineoplasticNauseaColorectal cancermedicine.medical_treatment030230 surgerylaw.invention03 medical and health sciences0302 clinical medicinePostoperative ComplicationsRandomized controlled triallawGermanymedicineHumansAgedNeoplasm Stagingbusiness.industryRectal NeoplasmsStandard treatmentPatient SelectionGastroenterologyPostoperative complicationRadiotherapy DosageMiddle Agedmedicine.diseaseTotal mesorectal excisionSurvival AnalysisNeoadjuvant Therapy3. Good healthSurgeryClinical trialRadiation therapyTreatment OutcomeChemotherapy Adjuvant030220 oncology & carcinogenesisQuality of LifeFemaleRadiotherapy AdjuvantFluorouracilmedicine.symptombusinessColorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
researchProduct

Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findin…

2018

Patients with primary refractory or relapsed acute myeloid leukemia (RR-AML) have very poor prognosis. Due to limited treatment options, some patients are treated with hypomethylating agents (HMAs) due to their tolerability. Little is known about the role of allogeneic hematopoietic stem cell transplantation (HSCT) following HMA therapy in this setting. We retrospectively analyzed an international cohort of 655 RR-AML patients who received HMA therapy to study patterns and outcomes with HSCT. Only 37 patients (5.6%) patients underwent HSCT after HMA therapy. The conditioning regimen was myeloablative in 57% and nonmyeloablative in 43%. Patients received matched unrelated donor, matched sibl…

AdultMalemedicine.medical_specialtyAntimetabolites AntineoplasticTransplantation ConditioningSurvivalmedicine.medical_treatmentSalvage therapyGraft vs Host DiseaseHypomethylating agentsHematopoietic stem cell transplantationTransplant03 medical and health sciences0302 clinical medicineRefractoryAMLimmune system diseasesInternal medicinehemic and lymphatic diseasesmedicineHumansTransplantation HomologousSurvival analysisAgedRetrospective StudiesSalvage TherapyTransplantationAML; Hypomethylating agents; Survival; Transplant; Adult; Aged; Antimetabolites Antineoplastic; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia Myeloid Acute; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation Homologousbusiness.industryHematopoietic Stem Cell TransplantationRetrospective cohort studyHematologyMiddle AgedSurvival AnalysisLeukemia Myeloid Acutesurgical procedures operativeTolerability030220 oncology & carcinogenesisCohortFemaleTransplantation Conditioningbusiness030215 immunology
researchProduct

Five years experience on 3,4-diaminopyridine phosphate in Lambert-Eaton syndrome: Case reports

2017

Abstract Rationale: To report our experience on 7 patients (4 males and 3 females), affected by nonparaneoplastic Lambert–Eaton myasthenic syndrome, treated with 3,4-diaminopyridine phosphate (3,4-DAPP) either alone or in combination with other immunosuppressants or steroids. Patient concerns: Patients have been evaluated at specific timepoints (ie, baseline and last 5 year follow-up), with neurological examination, autoantibodies against presynaptic voltage-gated Cav2.1 (P/Q type) calcium ion channel (VGCC) dosage, neurophysiological evaluation focusing on the increased amplitude of the compound muscle action potential (cMAP) after maximum voluntary effort, quantitative myasthenia gravis (…

AdultMalemedicine.medical_specialtyAzathioprineNeurological examination030204 cardiovascular system & hematologySeverity of Illness Index5300nonparaneoplastic-Lambert–Eaton myasthenic syndrome03 medical and health sciences0302 clinical medicinePrednisoneInternal medicineSeverity of illnessActivities of Daily LivingAzathioprinemedicineHumansMuscle StrengthClinical Case Report4-AminopyridineAdverse effect34-diaminopyridine phosphate; nonparaneoplastic-Lambert-Eaton myasthenic syndrome; 4-Aminopyridine; Activities of Daily Living; Adult; Azathioprine; Drug Therapy Combination; Female; Humans; Immunosuppressive Agents; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Muscle Strength; Prednisone; Severity of Illness Index; Treatment Outcome; Medicine (all)medicine.diagnostic_testbusiness.industry34-diaminopyridine phosphateGeneral MedicineMiddle Agedmedicine.diseaseMyasthenia gravisLambert-Eaton Myasthenic SyndromeTreatment OutcomeConcomitantPrednisoneDrug Therapy CombinationFemaleAmifampridinebusinessLambert-Eaton myasthenic syndrome030217 neurology & neurosurgeryImmunosuppressive Agentsmedicine.drugResearch Article
researchProduct

Therapy for Recurrent High-Grade Gliomas: Results of a Prospective Multicenter Study on Health-Related Quality of Life

2017

Objective To assess the impact of therapy on patients' health-related quality of life (HRQoL) in recurrent high-grade glioma (HGG) in an unselected cohort. Methods In this prospective multicenter study, we analyzed European Organization for Research and Treatment of Cancer Quality of Life core questionnaire and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Brain Neoplasm module questionnaires of 92 patients within 1 year after diagnosis of tumor recurrence of a HGG and respective treatment. We evaluated the influence of re-radiation, second- and third-line chemotherapies, and number of recurrent surgeries on summary scores for functioning, symptoms…

AdultMalemedicine.medical_specialtyBevacizumabAntineoplastic AgentsProcarbazinelaw.inventionCohort StudiesYoung Adult03 medical and health sciences0302 clinical medicineRandomized controlled trialQuality of lifelawSurveys and QuestionnairesInternal medicinemedicineHumansProspective StudiesKarnofsky Performance StatusAgedTemozolomidePerformance statusBrain Neoplasmsbusiness.industryCancerGliomaMiddle Agedmedicine.diseaseEurope030220 oncology & carcinogenesisCohortQuality of LifePhysical therapyFemaleRadiotherapy AdjuvantSurgeryNeurology (clinical)Neoplasm Recurrence Localbusiness030217 neurology & neurosurgerymedicine.drugWorld Neurosurgery
researchProduct

Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomograp…

2009

Abstract Purpose In the pre—positron emission tomography era, the Gruppo Italiano Studio Linfomi (GISL) investigated the feasibility and efficacy of a treatment based on a response-tailored number of doxorubicin/bleomycin/vinblastine/dacarbazine (ABVD) courses in 218 intermediate-stage Hodgkin lymphoma patients. Patients and Methods Patients with stage I/II showing at least one adverse prognostic factor and stage IIIA without adverse prognostic factors were recruited. Treatment included a first step of 3 ABVD courses, followed by an early-restaging. Patients in CR/CRu received 1 additional ABVD cycle, patients in PR received 3 more ABVD, and nonresponder patients went off study. Involved-fi…

AdultMalemedicine.medical_specialtyCancer ResearchAdolescentDacarbazinemedicine.medical_treatmentEarly restagingVinblastineBleomycinYoung AdultAdolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Doxorubicin; Female; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Vinblastine; Young AdultAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansProspective StudiesStage (cooking)Prospective cohort studyAgedNeoplasm StagingChemotherapyAntineoplastic Combined Chemotherapy Protocolmedicine.diagnostic_testbusiness.industryGeneral MedicineHematologyMiddle AgedCombined Modality TherapyHodgkin DiseaseSurgeryVinblastineRadiation therapyDacarbazineProspective StudieABVDOncologyDoxorubicinErythrocyte sedimentation ratePositron-Emission TomographyFemaleRadiologybusinessmedicine.drugHumanClinical lymphomamyeloma
researchProduct

Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma.

2011

Abstract Background There is no consensus about the most effective method for transarterial chemoembolisation of hepatocellular carcinoma. Aim The aim of this phase II trial was to compare the efficacy and toxicity of lipiodol transarterial chemoembolisation with amiodarone in association with pirarubicin or doxorubicin versus lipiodol transarterial chemoembolisation with anthracycline alone in a control group. Methods Patients with unresectable hepatocellular carcinoma and Child-Pugh A/B7 were considered eligible for the trial. transarterial chemoembolisation was repeated every 6 weeks for a maximum of 4 sessions. Results Thirteen patients were randomised in the amiodarone group, and 14 we…

AdultMalemedicine.medical_specialtyCarcinoma HepatocellularAnthracyclinePirarubicinAmiodaroneKaplan-Meier EstimateAmiodaroneGastroenterologyDisease-Free Survivallaw.inventionExcipientsEthiodized OilRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansChemoembolization TherapeuticAgedHepatologybusiness.industryLiver NeoplasmsGastroenterologyMiddle Agedmedicine.diseaseSurgeryClinical trialTreatment OutcomeDoxorubicinHepatocellular carcinomaLipiodolFemalebusinessmedicine.drugDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Transarterial Chemoembolization in Patients Not Eligible for Liver Transplantation: Single-Center Results

2008

OBJECTIVE. The purpose of this study was to evaluate the effectiveness of transarterial chemoembolization in the care of patients not eligible for liver transplantation.CONCLUSIONS. Prognosis depends on local response, Okuda score, α-fetoprotein level, and tumor size and is independent of the presence of portal venous thrombosis.

AdultMalemedicine.medical_specialtyCarcinoma HepatocellularPalliative careMitomycinmedicine.medical_treatmentContrast MediaLiver transplantationSingle CenterStatistics NonparametricmedicineHumansRadiology Nuclear Medicine and imagingIn patientChemoembolization TherapeuticSurvival analysisAgedAged 80 and overAntibiotics AntineoplasticChi-Square Distributionbusiness.industryLiver NeoplasmsPalliative CareIodized OilGeneral MedicineMiddle AgedPrognosismedicine.diseaseSurvival AnalysisIopamidolSurgeryVenous thrombosisTreatment OutcomeHepatocellular carcinomaFemaleRadiologyTomography X-Ray ComputedbusinessChi-squared distributionAmerican Journal of Roentgenology
researchProduct